75.5%
Chimeric Antigen Receptor T (CAR T) cell therapiesAB-3028mCRPCsolid tumorsTCGAhematological malignanciesmetastatic castration-resistant prostate cancer (mCRPC)The Cancer Genome Atlasprostate tumorsGTEx
…Background Chimeric Antigen Receptor T (CAR T) cell therapies have achieved curative outcomes in some hematological malignanc…